Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

ANNOUNCEMENT
IN RELATION TO SHARE OPTIONS AND SHARE AWARDS

Reference is made to the Schemes, pursuant to which the Company has granted certain share options and share awards to the eligible employees.

In recognition and acknowledgement of the contributions made to the Group and on the recommendation of the Remuneration Committee, the Board has resolved that (a) all unvested share options and share awards granted to (i) Mr. XIE Yuehui ("**Mr. XIE**") (who is an executive Director and chief executive officer of the Company and chairman of the Board), and Ms. WU Liping ("**Ms. WU**") and Mr. FANG Yu ("**Mr. FANG**") (each of whom is an executive Director), and (ii) certain other senior management and employees (including Mr. LIU Jianxiong ("**Mr. LIU**"), who is the company secretary, chief financial officer and executive vice president of the Company) under the Schemes shall be vested and become exercisable in full from the date hereof; and (b) the exercise period of all share options granted to Mr. XIE, Ms. WU, Mr. FANG and said certain other senior management and employees (including Mr. LIU) under the Share Option Schemes shall be extended. A summary of the share

options and share awards that are vested and extended pursuant to the aforesaid is set out below:

Individuals	Relevant Scheme	Number of unvested share options/ awards that shall become fully vested and exercisable pursuant to the aforesaid (a)	Number of already vested but unexercised share options that shall become fully exercisable pursuant to the aforesaid (b)	Aggregate number of share options that shall become fully vested and exercisable pursuant to the aforesaid (a)+(b)=(c)	New exercise period for share options	Exercise price for share options (HK$)
Directors						
Mr. XIE	2021 Share Option Scheme	3,220,000	1,380,000	4,600,000	Up to 24 January 2034	1.950
Ms. WU	2011 Share Option Scheme	N/A	500,000	500,000	Up to 31 March 2031	3.570
	2021 Share Option Scheme	1,887,000	4,403,000	6,290,000	Up to 10 December 2031	3.836
		11,375,000	4,875,000	16,250,000	Up to 24 January 2034	1.950
	2022 Share Award Scheme	14,666,667	N/A	N/A	N/A	N/A
Mr. FANG	2011 Share Option Scheme	N/A	400,000	400,000	Up to 31 March 2031	3.570
	2021 Share Option Scheme	390,000	910,000	1,300,000	Up to 10 December 2031	3.836
		11,200,000	4,800,000	16,000,000	Up to 24 January 2034	1.950
	2022 Share Award Scheme	10,666,667	N/A	N/A	N/A	N/A
Other senior management and employees						
Other senior management and employees	2011 Share Option Scheme	N/A	4,400,000	4,400,000	Up to 31 March 2031	3.570
	2021 Share Option Scheme	1,818,000	4,242,000	6,060,000	Up to 12 November 2031	3.590
		390,000	910,000	1,300,000	Up to 10 December 2031	3.836
		40,285,000	17,265,000	57,550,000	Up to 24 January 2034	1.950
	2022 Share Award Scheme	53,112,503	N/A	N/A	N/A	N/A

Unless the context otherwise requires, the following expressions shall have the following meanings in this announcement:

"2011 Share Option Scheme"	the share option scheme adopted by the Company on 22 October 2011 which was terminated on 17 September 2021
"2021 Share Option Scheme"	the share option scheme of the Company adopted on 17 September 2021
"2022 Share Award Scheme"	the share award scheme adopted by the Company on 3 March 2022 (as amended and restated on 23 May 2025 and 13 February 2026) involving existing Shares
"Board"	the board of Directors
"Chairman"	the chairman of the Board
"Company"	LifeTech Scientific Corporation, a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange (stock code: 1302)
"Director(s)"	the director(s) of the Company
"Group"	the Company and its subsidiaries
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with GEM
"PRC"	People's Republic of China, which, for the purposes of this announcement, excludes Hong Kong, the Macao Special Administrative Region of the PRC and Taiwan
"Remuneration Committee"	the remuneration committee of the Board
"Schemes"	the Share Option Schemes and 2022 Share Award Scheme

"Share(s)"	ordinary share(s) of US$0.00000125 each in the share capital of the Company
"Share Option Schemes"	the 2011 Share Option Scheme and 2021 Share Option Scheme
"Shareholder(s)"	holder(s) of the issued Shares
"Stock Exchange"	The Stock Exchange of Hong Kong Limited

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 6 November 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Ms. WU Liping and Mr. FANG Yu being executive Directors; and Mr. JIANG Feng, Mr. ZHOU Luming and Ms. CHEN Dongxia being independent non-executive Directors.